Design, Synthesis and Neuropharmacological Evaluation of Thiophene Incorporated Isoxazole Derivatives As Antidepressant and Antianxiety Agents

Total Page:16

File Type:pdf, Size:1020Kb

Design, Synthesis and Neuropharmacological Evaluation of Thiophene Incorporated Isoxazole Derivatives As Antidepressant and Antianxiety Agents ORIGINAL RESEARCH DESIGN, SYNTHESIS AND NEUROPHARMACOLOGICAL EVALUATION OF THIOPHENE INCORPORATED ISOXAZOLE DERIVATIVES AS ANTIDEPRESSANT AND ANTIANXIETY AGENTS Jagdish Kumar1, Mymoona Akhtar2, Chanda Ranjan3, Gita Chawla4,* 1,2,34Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi-110062, India. *Corresponding Author: E-mail: [email protected] ABSTRACT A series of 5-substituted phenyl-3-(thiophen-2-yl)-4, 5-dihydro-1, 2-oxazoles (2a-l) was synthesized by reacting appropriate chalcones of 2-acetyl thiophene with hydroxylamine hydrochloride in the presence of dry pyridine. The newly synthesized compounds were characterized by IR, 1HNMR, 13CNMR and mass spectral data. All the compounds were evaluated for their antidepressant and antianxiety activities in mice by forced swimming test and elevated plus maze method respectively. Test compounds and imipramine were administered intraperitoneally in antidepressant study at dose of 10 mg/kg. Similarly to study antianxiety activity, test compounds at the dose of 10 mg/kg and diazepam at the dose of 2 mg/kg were administered intraperitoneally. However, preliminary antidepressant screening of compounds (2a-l) revealed that none of the compounds showed antidepressant activity except for compound 2k which moderately (P<0.05) reduced the duration of immobility time. This compound was also tested in-vitro for its MAO inhibitory effect. Compound 2f showed highest antianxiety activity compared to diazepam and did not show neurotoxicity in rotarod test. The compounds were also studied for pharmacokinetic parameters and was observed that compound 2f displayed good ADME properties. Keywords: Thiophene, isoxazole, antianxiety and antidepressant. INTRODUCTION the anti-anxiety drugs act primarily by facilitating Depression is a life threatening illness that inhibitory GABAergic transmission [4]. The affects the major part of population across the globe worldwide experience among clinicians and [1]. It is associated with pathological change in mood researchers is that anxiety and depression commonly state. Antidepressants can elevate mood in depressive co-exist in clinical samples and in general population state. Practically, all antidepressants affect [5]. During literature survey it was found that isoxazole monoaminergic transmission in the brain. nucleus is one of the important and widely exploited Antidepressants affect the reuptake/ metabolism of heterocyclic ring for the development of bioactive biogenic amines. Antidepressants are generally molecules. Increasing evidence suggests that classified as tricyclic antidepressants (including NA, isoxazole derivatives possess a broad spectrum of 5HT reuptake inhibitors, selective serotonin reuptake biological activities such as antianxiety, [6-7] inhibitors (SSRIs), noradrenaline reuptake inhibitors antidepressant [8, 9] anti-stress [10], MAO inhibitory [11] (NRIs) and MAO inhibitors [2]. Earlier MAO inhibitors and anticonvulsant [12]. Isocarboxazide is an isoxazole were abandoned due to their side effects such as derivative having antidepressant action available in hepatotoxicity, orthostatic hypotension and the the market which is a non-selective MAO inhibitor. ‘cheese effect’ characterized by hypertensive crisis. Recently antidepressant activity of isoxazole ether This was due to non-selective and irreversible MAO scaffold is also reported [13]. Many isoxazole nucleus inhibition. But identification of two isoforms i.e. containing compounds have also been patented for MAO A and MAO B has renewed the interest in their antidepressant and antianxiety activities [14-18]. biological potential of these compounds. MAO A and Similarly thiophene containing compounds have been MAO B are Flavin adenine dinucleotide (FAD) reported to exhibit antidepressant [19-20] and antianxiety containing enzymes. MAO A preferably metabolizes activities [21]. Duloxetine, Etizolam, Teniloxazine, serotonin (5-HT), adrenaline and noradrenaline Tigabine etc. are the thiophene nucleus containing whereas MAO B metabolizes β-phenyl ethylamine antidepressant and antianxiety drugs being marketed. and benzylamine. MAO A inhibitors are useful in the Thiophene analogues also have been well reported as treatment of depression and anxiety while MAO B MAO inhibitors [22]. could be used to treat Parkinson’s disease and However, during literature survey it was Alzheimer’s disesase. Efforts have been oriented found that thiophene ring has not been linked with towards discovery of reversible and selective isoxazoles so far. This motivated us to synthesize inhibitors of MAO A/ MAO B [3]. Similarly, anxiety is hybrid compounds that comprise both the isoxazole an emotional state associated with uneasiness, and the thiophene ring systems with the hope of discomfort and fear about some future threat. Most of developing potent compounds with antianxiety and International Journal of Pharmaceutical Chemistry and Analysis; April-June 2015;2(2):74-83 74 Kumar et al. Design, Synthesis and Neuropharmacological Evaluation of Thiophene Incorporated Isoxazole… antidepressant effects (Figure 1). We report herein the General procedure for the preparation of synthesis of a series of 5-substituted phenyl-3- 5-substituted phenyl - 3 - (thiophen – 2 - yl) - 4, 5- (thiophen-2-yl)-4,5-dihydro-l, 2-oxazole derivatives dihydro-1, 2-oxazoles (2a-l). To the solution of (2a-l). A computational study for prediction of ADME appropriate chalcone (0.01 mol) in absolute ethanol properties of titled compounds (2a-1) was performed (50 ml) was added dry pyridine (1 ml) and for the prediction of ADME properties. This study hydroxylamine hydrochloride (0.01 mol). The includes lipophilicity data also which is an important contents were refluxed for 8-10 h and left overnight. requirement for neuropharmacological activity. The solvent was evaporated off and the residue was ADME properties of newly synthesized isoxazole poured into ice cold water. The solid mass which was derivatives were calculated using online separated out was filtered, washed with water, dried molinspiration software. These compounds were and crystallized from methanol. tested for their in-vivo antidepressant activity by forced swimming test (FST). Compound 2k showing 5-phenyl-3-(thiophen-2-yl)-4,5-dihydro-1,2-oxazole moderate antidepressant activity was screened for (2a). MAO inhibitory activity. All the twelve compounds FTIR [KBr, cm-1]: 676 (C-S), 1356 (C-O-N stretch), were evaluated for their antianxiety activity by 1659 (C=N stretch). 1H NMR [300 MHz, δ ppm, elevated plus maze method. Neurotoxicity was DMSO-d6]: 3.52 (1H, dd, J = 9.3, 6.8 Hz, CH), 3.74 determined by rotarod toxicity test. Few of the final (1H, dd, J = 11.3, 6.8 Hz, CH), 7.12-7.65 (8H, m, compounds have been reported by Ingle et al. [23] but ArH), 5.92 (1H, dd, J = 9.3, 11.3 Hz, CH), 7.31 and δ have not been tested for their pharmacological 7.73 (dd, 1H, (thiophene C-CH), 7.61 (t, 1H, activities. (thiophene CH-S). 13CNMR [75 δ ppm, MHz, δ ppm, DMSO-d6]: 44.13, 82.09, 125.67, d126.91, 127.41, EXPERIMENTAL d127.57, 130.31, 130.38, 138.17, 140.03, 147.82, MS: + Chemistry: m/z 229 (M ); Anal. Calcd for C13H11NOS: C, 68.09, All the chemicals used were of laboratory H, 4.84, N, 6.11, Found: C, 68.18, H, 4.90, N, 6.16%. grade and procured from E. Merck (Germany) and S.D. Fine Chemicals (India). Melting points were 5-(2-chlorophenyl)-3-(thiophen-2-yl)-4,5-dihydro- determined by the open tube capillary method and are 1,2-oxazole (2b). uncorrected. The Thin layer chromatography (TLC) FTIR [KBr, cm-1]: 676 (C-S), 1357 (C-O-N stretch), plates (silica gel G) were used to confirm the purity of 1662 (C=N stretch). 1H NMR [300 MHz, δ ppm, commercial reagents used, compounds synthesized DMSO-d6]: δ 3.58 (1H, dd, J = 9.4, 7.8 Hz, CH), 3.73 and to monitor the reactions as well. Two different (1H, dd, J = 11.5, 7.8 Hz, CH), 6.00 (1H, dd, J = solvent systems: toluene: ethyl acetate: formic acid 9.4,11.5 Hz, CH), 7.15-7.65 (7H, m, ArH), 7.32 and δ (5:4:1) and benzene: acetone (9:1), were used to run 7.68 (dd, 1H, (thiophene C-CH), 7.62(t, 1H, the TLC and spots were located under iodine (thiophene CH-S); 13CNMR [75 MHz, δ ppm, DMSO- vapors/UV light. IR spectra were obtained on a Perkin- d6]: δ 44.43, 78.63, 126.65, 127.41, 129.21, 129.36, Elmer 1720 FT-IR spectrometer (KBr Pellets). 1H 129.58, 130.35, 130.40, 134.32, 135.36, 138.20, NMR and 13C NMR spectra were recorded in DMSO- 147.82, MS: m/z 263.74 (M+), 265.74 (M+2); Anal. d6/CDCl3 on a Bruker 300 MHz and 75 MHz Calcd for C13H10ClNOS: C, 69.20, H, 3.82, N, 5.31, spectrometer, respectively, using tetramethylsilane Found: C, 69.33, H, 3.96, N, 5.34%. (TMS) as the internal reference (chemical shift was measured in δ ppm). Mass spectra (ESI-Q-TOF) were 5-(3-chlorophenyl)-3-(thiophen-2-yl)-4,5-dihydro- measured on a Waters mass spectrometer with an ESI 1,2-oxazole (2c). (Electron spray ionization) source. FTIR [KBr, cm-1]: 1652 (C=N stretch), 1363 (C-O-N General procedure for the preparation of stretch), 669 (C-S). 1H NMR [300 MHz, δ ppm, 3-(substituted phenyl)-1-(thiophen-2-yl)prop-2-en- DMSO-d6]: 3.57 (1H, dd, J = 9.1, 7.8 Hz, CH), 3.74 1-ones (chalcones) (1a-l) A mixture of 2-acetyl (1H, dd, J = 11.1, 7.8 Hz, CH), 5.99 (1H, dd, J = 9.1, thiophene (1) (0.01 mol) and substituted aromatic 11.1 Hz, CH), δ 6.84-7.64 (7H, m, ArH), 7.35 and δ aldehyde (0.01 mol) in absolute ethanol (30 mL) was 7.71 (dd, 1H, (thiophene C-CH), 7.67(t, 1H, stirred at room temperature in the presence of base (thiophene CH-S). 13CNMR [75 MHz, δ ppm, DMSO- (alc.
Recommended publications
  • British Brand Name
    Standardisation framework for the Maudsley staging method for treatment resistance in depression Article (Supplemental Material) Fekadu, Abebaw, Donocik, Jacek G and Cleare, Anthony J (2018) Standardisation framework for the Maudsley staging method for treatment resistance in depression. BMC Psychiatry, 18 (100). pp. 1-13. ISSN 1471-244X This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/75748/ This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher’s version. Please see the URL above for details on accessing the published version. Copyright and reuse: Sussex Research Online is a digital repository of the research output of the University. Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available. Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. http://sro.sussex.ac.uk
    [Show full text]
  • 1 Supplemental Figure 1: Illustration of Time-Varying
    Supplemental Material Table of Contents Supplemental Table 1: List of classes and medications. Supplemental Table 2: Association between benzodiazepines and mortality in patients initiating hemodialysis (n=69,368) between 2013‐2014 stratified by age, sex, race, and opioid co‐dispensing. Supplemental Figure 1: Illustration of time‐varying exposure to benzodiazepine or opioid claims for one person. Several sensitivity analyses were performed wherein person‐day exposure was extended to +7 days, +14 days, and +28 days beyond the outlined periods above. 1 Supplemental Table 1: List of classes and medications. Class Medications Short‐acting benzodiazepines Alprazolam, estazolam, lorazepam, midazolam, oxazepam, temazepam, and triazolam Long‐acting benzodiazepines chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, flurazepam Opioids alfentanil, buprenorphine, butorphanol, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphine, meperidine, methadone, morphine, nalbuphine, nucynta, oxycodone, oxymorphone, pentazocine, propoxyphene, remifentanil, sufentanil, tapentadol, talwin, tramadol, carfentanil, pethidine, and etorphine Antidepressants citalopram, escitalopram, fluoxetine, fluvozamine, paroxetine, sertraline; desvenlafaxine, duloxetine, levomilnacipran, milnacipran, venlafaxine; vilazodone, vortioxetine; nefazodone, trazodone; atomoxetine, reboxetine, teniloxazine, viloxazine; bupropion; amitriptyline, amitriptylinoxide, clomipramine, desipramine, dibenzepin, dimetacrine, dosulepin, doxepin, imipramine, lofepramine, melitracen,
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Is Hyperbaric Oxygen Therapy an Effective Treatment for Autism
    Running Head: VETERANS, ANTIDEPRESSANTS, AND SUICIDE 1 Veterans, Antidepressants, and Suicide: A Systematic Review of Adverse Events Daniel J. Dunleavy1 Jeffrey R. Lacasse2 Shannon Hughes3 Cassandra Olson4 MaKenna Woods2 1 Florida State University, Center for Translational Behavioral Science 2 Florida State University, College of Social Work 3 Colorado State University, College of Health and Human Sciences 4 Florida State University, College of Health and Human Sciences Author Note Daniel J. Dunleavy https://orcid.org/0000-0002-3597-7714 The authors have no conflicts of interest to disclose. Correspondence concerning this article should be addressed to Daniel J. Dunleavy, Center for Translational Behavioral Science, Florida State University, 2010 Levy Ave, Building B, Suite B0266, Tallahassee, FL 32310. Email: [email protected] VETERANS, ANTIDEPRESSANTS, AND SUICIDE 2 Abstract Background: Military veterans represent a disproportionate number of suicides that occur in the U.S. Antidepressants have been associated with increased risk of suicidal thoughts/behaviors and completed suicide. Given the high number of psychotropic medications prescribed to the veteran population, it is salient that any relationship between veteran suicide and antidepressants be explored. Method: A preregistered systematic review was conducted of empirical studies from 1988-2018. Studies were identified through electronic bibliographic databases. Results: A total of 25 studies met eligibility criteria. Studies reviewed only minimally explored adverse effects of antidepressants.
    [Show full text]
  • Antidepressants for Neuropathic Pain (Review)
    Antidepressants for neuropathic pain (Review) Saarto T, Wiffen PJ This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2007, Issue 4 http://www.thecochranelibrary.com Antidepressants for neuropathic pain (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 5 DISCUSSION ..................................... 11 AUTHORS’CONCLUSIONS . 12 ACKNOWLEDGEMENTS . 12 REFERENCES ..................................... 13 CHARACTERISTICSOFSTUDIES . 19 DATAANDANALYSES. 65 Analysis 1.1. Comparison 1 Global improvement - number of patients with moderate pain relief or better, Outcome 1 Amitriptylineversusplacebo. 67 Analysis 1.2. Comparison 1 Global improvement - number of patients with moderate pain relief or better, Outcome 2 Desipraminevsplacebo. 68 Analysis 1.3. Comparison 1 Global improvement - number of patients with moderate pain relief or better, Outcome 3 Imipraminevsplacebo. 68 Analysis 1.4. Comparison 1 Global improvement - number of patients with moderate pain relief or better, Outcome 4 Other antidepressants vs placebo. ..... 69 Analysis 1.5. Comparison 1 Global improvement - number of patients
    [Show full text]
  • Can You Take Shrooms on Antidepressants?
    Can You Take Plant Medicine cept On Antidepressants? Many people who want to take plant medicine, are already on a prescription and want to know whether their medication is safe to combine with psychedelic substances. Although psilocybin has been shown to effectively treat depression and a number of other mental health conditions, there are some antidepressant medications that could have dangerous or undesirable interactions with the substance. Life Synergy always recommends checking in with your healthcare provider before mixing any psychedelic with your medications. However, below is a guide to what we know about some of the most common medications, and the risky combinations of psilocybin and antidepressants that you should avoid. How Does Psilocybin Work? Psilocybin is the main psychoactive component of psychedelic mushrooms, also known as “shrooms” “psychedelic truffles” or “magic mushrooms.” Since its scientific discovery in 1958, psilocybin has been used extensively in clinical research, with over 40,000 patients receiving this drug without serious adverse events. Psilocybin is converted in the stomach to psilocin, which crosses the blood-brain barrier, and then works by exerting partial agonist effects on brain 5-hydroxytryptamine (5-HT) 2A receptors, among others, and can alter normal waking consciousness. Common effects include unusual and colourful visuals with eyes open or shut, disintegration of ‘self’ or ‘ego’, unconstrained explorative thinking, cognitive, affective and perceptual changes, and a sense of connectedness to self, others and the world. Ingesting psilocybin, in the form of mushrooms or truffles, produces an intense psychedelic experience that lasts several hours. By altering several different neurotransmitter systems in the brain, magic mushrooms or truffles activate serotonergic receptors on neurons, causing several brain systems to significantly change, and a wave of unique excitatory activity to spread throughout the main perceptual centers of the mind.
    [Show full text]
  • Supplemental Digital Content 1 Search Strategy (First Conducted on January 17, 2014; Second Retrieval on November 5, 2014)
    Supplemental Digital Content 1 Search strategy (first conducted on January 17, 2014; second retrieval on November 5, 2014) Cochrane Central Register of Controlled Trials and MEDLINE via OVID 1. exp chronic pain/ 2. Pain Management/ 3. Pain Measurement/ 4. pain*.mp. 5. 1 or 2 or 3 or 4 11. exp neoplasms/ 12. (neoplas* or cancer* or tumor* or tumour* or carcinoma* or malignan* or oncolog* or metasta* or sarcoma* or adenocarcinoma* or choriocarcinoma* or leukemia* or leukaemia*).mp. 13. 11 or 12 14. exp Anticonvulsants/ or exp Antidepressive Agents/ 15. (anticonvulsant* or antiepilept* or antidepressant* or anti-convulsant* or anti-epilept* or anti-depressant*).mp. 16. (acetazolamide or carbamazepine or clonazepam or divalproex or ethosuximide or ethotoin or felbamate or fosphenytoin or gabapentin or lacosamide or lamotrigine or levetiracetam or methsuximide or oxcarbazepine or phenobarbital or phenobarbitone or phenytoin or pregabalin or primidone or tiagabine or topiramate or trimethadione or valproate or valproic or vigabatrin or zonisamide).mp. 17. (agomelatine or amesergide or amineptine or amitriptyline or amoxapine or aripiprazole or benactyzine or brofaromine or bupropion or butriptyline or chlorimipramine or cianopramine or citalopram or clomipramine or clorgyline or clovoxamine or demexiptiline or desipramine or desvenlafaxine or dibenzepin or dimetacrine tartrate or dosulepin or dothiepin or doxepin or duloxetine or escitalopram or etoperidone or femoxetine or fezolamine fumarate or fluoxetine or fluvoxamine or ifoxetine or imipramine
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0050713 A1 Malakhov Et Al
    US 2015.0050713A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0050713 A1 Malakhov et al. (43) Pub. Date: Feb. 19, 2015 (54) TECHNOLOGY FOR THE PREPARATION OF Publication Classification MCROPARTICLES (51) Int. Cl. (71) Applicant: Ansun Biopharma, Inc., San Diego, CA CI2N 9/96 (2006.01) (US) CI2N 7/00 (2006.01) CI2N IS/II3 (2006.01) (72) Inventors: Michael P. Malakhov, San Francisco, C07D 305/.4 (2006.01) CA (US); Fang Fang, Rancho Santa Fe, C07K 4/765 (2006.01) CA (US) C07K9/00 (2006.01) (52) U.S. Cl. CPC ................ CI2N 9/96 (2013.01); C07K 14/765 (21) Appl. No.: 14/341,502 (2013.01); C07K9/008 (2013.01): CI2N 15/113 (2013.01); C07D 305/14 (2013.01); (22) Filed: Jul. 25, 2014 CI2N 7/00 (2013.01); C12N 2770/00051 (2013.01) O O USPC ........... 435/188: 530/363; 530/350, 530/367; Related U.S. Application Data 530/385:536/16.8; 536/13.7: 540/336; 530/317; (63) Continuation of application No. 13/874,424, filed on 536/24.5; 530/328; 552/203; 549/510; 435/238 Apr. 30, 2013, now abandoned, which is a continuation (57) ABSTRACT of application No. 13/250,653, filed on Sep. 30, 2011, Mi h duced b tacti lution of a now abandoned, which is a continuation of application 1crospneres are produced by contacting a sol No. 12/179.520, filed on Jul 24, 2008, now aban- macromolecule or small molecule in a solvent with an ant1 doned sa- 1 ws s s Solvent and a counterion, and chilling the solution.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]
  • Depression in Adults: Treatment and Management
    National Institute for Health and Care Excellence Consultation draft Depression in adults: treatment and management Appendix U2.10: Text from CG90 Appendix 17d that has been deleted NICE Guideline Appendices May 2018 1 Disclaimer Healthcare professionals are expected to take NICE clinical guidelines fully into account when exercising their clinical judgement. However, the guidance does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of each patient, in consultation with the patient and/or their guardian or carer. Copyright National Institute for Health and Care Excellence [2018]. All rights reserved. Subject to Notice of rights. 2 Appendix 17d: clinical studies characteristics tables – management of subthreshold depressive symptoms Contents Service delivery – studies excluded in the guideline update……………………………………………………………………. 1 Service delivery – relapse prevention – studies excluded in the guideline update…………………………………………… 3 Psychological and psychosocial interventions – new studies in the guideline update………………………………………. 4 Pharmacological interventions – new studies in the guideline update………………………………………………………... 11 Pharmacological interventions – relapse prevention - new studies in the guideline update……………………………….. 24 3 Service delivery - studies excluded in the guideline update Characteristics of Excluded Studies Reference ID Reason for Exclusion ADLER2004 Dythymia<50% so in major depression group BRUCE2007 Assessment of depression GLICK1986 Not diagnosis of depression
    [Show full text]